News

Digital monitoring checks for possible malnutrition in hospital patients

Cardia arrest: heart rate in pulseless electrical activity (PEA) is a good prognostic tool

Prestigious HFSP grants demonstrate IMBA’s excellence in Stem Cell Research

Cancer School CCC Vienna: better informed, better treatment outcome

Scientific exchange is a two-way street

123sonography: E-learning platform for clinicians expands to Boston

Arsanis Out-Licenses Preclinical Stage E. coli Monoclonal Antibodies

New international partnership promises great potential for next-­generation biopharmaceuticals

Valneva to Present on Lyme and Zika at the 18thWorld Vaccine Congress in Washington, D.C.

The “eternal youth” of cancer cells

Mitral regurgitation influences the course of chronic heart failure

Alzheimer´s disease: patients exhibit changes in certain bloos lipids that are typical of premature ageing

Austrian Society For Stem Cell Research Founded At IMBA

Valneva Reports Positive Phase I Interim Results for Its Lyme Vaccine Candidate VLA15

Seed-Financing round for contextflow

Arsanis Granted Key Patents for ASN100 Covering Cross-Neutralizing S. aureus Toxin Antibodies

Valneva Initiates Phase I Clinical Study to Evaluate Its Single-Shot Vaccine Candidate against Chikungunya

Arsanis Reports Financial Results and Highlights for Fourth Quarter and Full Year 2017

CEPI Partners with Themis Bioscience to Advance Vaccines Against Lassa Fever and MERS

AFFiRiS Announces Results of a Phase I Clinical Study Using AFFITOPEs® PD01A and PD03A, Confirming Safety and Tolerability for Both Compounds as well as Immunogenicity for PD01A in Early MSA patients